Simvastatin Plus Nitric Oxide Synthase Inhibition Modulates Remote Organ Damage Following Skeletal Muscle Ischemia-Reperfusion Injury
Authors:
- A. KhannaAKA. Khanna
- P. E. LawsPLP. E. Laws
- J. B. F. FieldJFJ. B. F. Field
- R. A. FitridgeRFR. A. Fitridge
- 1 January 2008
- journal article
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 21 (3) , 119-126
Abstract
Ischemia-reperfusion injury (IRI) to the lower extremities causes both local damage and serious dysfunction to remote organs, including lungs and kidneys. However, effective therapies are not available. This study aims to determine if simvastatin reduced the severity of remote damage following IRI. Rats were given simvastatin before hind limb IRI. Lung and kidney tissues were assessed for neutrophil infiltration using myeloperoxidase assays and basement membrane damage by quantitative immunohistochemical measurement of collagen IV. The effect of nitric oxide synthase (NOS) inhibition on remote damage after IRI and simvastatin was assessed using the NOS inhibitor, L-NIO. Simvastatin (2 mg/kg) protected kidneys against IRI-induced neutrophil infiltration. Simvastatin also inhibited the IRI-induced activation of MMP-9 in the lungs. However, paradoxically, simvastatin exacerbated IRI-induced neutrophil infiltration into the lungs. IRI induced collagen IV degradation in the lungs but not in the kidneys. The degree of collagen breakdown in the lungs was significantly ameliorated by 2 mg/kg simvastatin. NOS inhibition markedly protected both the lungs and the kidneys against IRI-induced neutrophil infiltration but did not alter collagen IV degradation. Administration of simvastatin to L-Nio-treated animals enhanced the degree of protection against IRI-induced neutrophil infiltration in the kidneys but not in the lungs. Simvastatin protects against remote IRI-induced damage in the lungs and kidneys, suggesting statins may reduce the severity of IRI during major vascular surgery.Keywords
This publication has 31 references indexed in Scilit:
- EXPRESSION OF CONCERN: Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type‐1 diabetic miceBritish Journal of Pharmacology, 2007
- Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditionsJournal of Vascular Surgery, 2007
- Pravastatin reduces microvascular basal lamina damage following focal cerebral ischemia and reperfusionEuropean Journal of Neuroscience, 2006
- Pravastatin attenuates tourniquet-induced skeletal muscle ischemia reperfusion injuryActa Orthopaedica, 2006
- Reperfusion injury in skeletal muscle is reduced in inducible nitric oxide synthase knockout miceJournal of Applied Physiology, 2004
- The Role of Statins in Vascular DiseaseEuropean Journal of Vascular and Endovascular Surgery, 2004
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Atorvastatin inhibition of cytokine‐inducible nitric oxide synthase expression in native endothelial cellsin situBritish Journal of Pharmacology, 2002
- Exogenous and Endogenous Nitric Oxide but Not iNOS Inhibition Improves Function and Survival of Ischemically Injured LiversJournal of Investigative Surgery, 2001
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998